Literature DB >> 24726579

Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.

Gagan Fervaha1, Ofer Agid2, Hiroyoshi Takeuchi3, George Foussias2, Gary Remington2.   

Abstract

The field of schizophrenia is redefining optimal outcome, moving beyond clinical remission to a more comprehensive model including functional recovery and improved subjective well-being. Although numerous studies have evaluated subjective outcomes within the domain of subjective quality of life in patients with schizophrenia, less is known about global evaluations of subjective well-being. This study examined the effects of antipsychotic medication on overall life satisfaction in patients with chronic schizophrenia. Data were drawn from the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study, where participants with a DSM-IV diagnosis of schizophrenia were randomized to receive olanzapine, perphenazine, quetiapine, risperidone or ziprasidone under double-blind conditions (N=753). The primary outcome measure was prospective change in subjectively evaluated overall life satisfaction scores following 12 months of antipsychotic treatment. Psychopathology, medication side effects and functional status were also evaluated, among other variables. Patients experienced modest improvements in overall life satisfaction (d=0.22, p<0.001), with no differences between antipsychotic medications (all tests, p>0.05). Change in severity of positive, negative, and depressive symptoms as well as functional status each demonstrated a small, albeit statistically significant, association with change in life satisfaction (r=0.10-0.21, p׳s<0.01). In a multivariate regression model, change in clinical symptoms and functional status had limited independent predictive value for change in life satisfaction scores (explained variance <3%). These data suggest that despite antipsychotic medications being effective for symptom-based psychopathology, such clinical effectiveness does not necessarily translate to improved general satisfaction with life. Clinicians should be aware that these two domains are not inextricably linked.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Antipsychotic treatment; Life satisfaction; Outcome; Quality of life; Schizophrenia; Well-being

Mesh:

Substances:

Year:  2014        PMID: 24726579     DOI: 10.1016/j.euroneuro.2014.03.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

Review 1.  Psychosis.

Authors:  David B Arciniegas
Journal:  Continuum (Minneap Minn)       Date:  2015-06

2.  Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.

Authors:  Jimmy Lee; Hiroyoshi Takeuchi; Gagan Fervaha; Gwen Li Sin; George Foussias; Ofer Agid; Saeed Farooq; Gary Remington
Journal:  Can J Psychiatry       Date:  2015-11       Impact factor: 4.356

3.  Compensatory Cognitive Training for psychosis: Effects on negative symptom subdomains.

Authors:  Zanjbeel Mahmood; Jillian M R Clark; Elizabeth W Twamley
Journal:  Schizophr Res       Date:  2018-10-04       Impact factor: 4.939

4.  Confirmatory Factor Analysis and Differential Relationships of the Two Subdomains of Negative Symptoms in Chronically Ill Psychotic Patients.

Authors:  Annemarie P M Stiekema; Edith J Liemburg; Lisette van der Meer; Stynke Castelein; Roy Stewart; Jaap van Weeghel; André Aleman; Richard Bruggeman
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

5.  Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.

Authors:  Steven G Potkin; Jean-Yves Loze; Carlos Forray; Ross A Baker; Christophe Sapin; Timothy Peters-Strickland; Maud Beillat; Anna-Greta Nylander; Peter Hertel; Simon Nitschky Schmidt; Anna Eramo; Karina Hansen; Dieter Naber
Journal:  Int J Neuropsychopharmacol       Date:  2017-01-01       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.